Kenya is making steady progress toward producing its first locally manufactured vaccines, with the initial batch expected by the end of 2027. The government-funded vaccine manufacturing facility has completed its first phase, while the second phase is now underway, focusing on system integration and the installation of key equipment, including advanced fill-and-finish technology.<\/p>\n
\nHealth Cabinet Secretary Aden Duale highlighted the milestone during high-level talks with the board and senior management of the Kenya BioVax Institute, reaffirming the government\u2019s commitment to local vaccine manufacturing as a critical pillar of universal health coverage and national health security.<\/p>\n
\nThe engagement emphasised the Institute\u2019s mandate to manufacture and commercialise safe, high-quality vaccines and other essential health products needed to strengthen Kenya\u2019s preparedness for public health emergencies.<\/p>\n
\nDiscussions also noted Kenya\u2019s achievement of World Health Organisation Maturity Level 3, a key regulatory benchmark attained with support from the Pharmacy and Poisons Board and the National Quality Control Laboratory.<\/p>\n
\n“This achievement enhances regulatory confidence, supports Kenya\u2019s UHC goals, and reinforces the country\u2019s position as an emerging pharmaceutical manufacturing hub in Africa, while contributing to economic growth under the Bottom-Up Economic Transformation Agenda,” said Duale.<\/p>\n
\nWorld Bank support<\/p>\n
\nCS Duale further revealed that the Kenya BioVax Institute will benefit from World Bank support through the Regional Health Emergency Preparedness, Response, and Resilience program, aimed at boosting pharmaceutical production capacity and strengthening emergency response systems.<\/p>\n
\nDuring an interactive session with staff, the Cabinet Secretary emphasised integrity, transparency, and accountability in public service, noting that these principles are essential for delivering effective and people-centred healthcare.<\/p>\n
\nThe Kenya BioVax Institute is a state-owned pharmaceutical company established in 2021 with the core mission of manufacturing, packaging, and commercialising human vaccines and other health products for Kenya and beyond.<\/p>\n
\nIt was created to help the country become self-sufficient in vaccine supply, particularly as Kenya\u2019s support from international partners like Gavi is expected to decline in the coming years.<\/p>\n
\nThe Covid-19 pandemic highlighted the risks of relying on imports, motivating the government to build local production capacity.<\/p>\n
\nThe institute is focused on producing both routine and emergency human vaccines\u2014immunisations that protect against common diseases as well as vaccines needed during outbreaks.<\/p>\n
\nInitial vaccine products being prepared for local manufacturing include shots for typhoid and pneumonia, which are expected to benefit millions of children once production begins. Plans include vaccines for tetanus, hepatitis B, polio, cholera, Ebola, and other critical immunisations.<\/p>\n
\nBeyond vaccines, BioVax\u2019s mandate includes producing other biomedical products and technologies, such as biosimilar therapies, insulin, snake anti-venom, medical infusions, and diagnostic tools\u2014all aimed at improving access to quality health care in Kenya and the region.<\/p>\n
\nThe BioVax Institute has also partnered with research bodies like the Kenya Medical Research Institute (KEMRI) to support vaccine development and capacity building.<\/p>\n
\nThis collaboration helps move research from discovery to manufacturing, boosting Kenya\u2019s biotechnology capabilities and enabling more products to be made locally.<\/p>\n
\nLocal vaccine production through institutions like the Kenya BioVax Institute aligns closely with the World Health Organisation\u2019s broader goals for vaccine access, equity, and health security.<\/p>\n","protected":false},"excerpt":{"rendered":"Kenya is making steady progress toward producing its first locally manufactured vaccines, with the initial batch expected by…\n","protected":false},"author":2,"featured_media":20101,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[11622,12540,12542,84,3144,80,12537,12535,12539,12541,10710,12538,2024,12536],"class_list":{"0":"post-20100","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kenya","8":"tag-aden-duale","9":"tag-covid-19-lessons","10":"tag-gavi-transition","11":"tag-headlines","12":"tag-health","13":"tag-kenya","14":"tag-kenya-biovax-institute","15":"tag-kenya-on-track-to-produce-its-first-locally-manufactured-vaccines-by-2027","16":"tag-pharmaceutical-industry","17":"tag-public-health-preparedness","18":"tag-universal-health-coverage","19":"tag-vaccine-manufacturing","20":"tag-world-bank","21":"tag-world-health-organisation"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts\/20100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/comments?post=20100"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/posts\/20100\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/media\/20101"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/media?parent=20100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/categories?post=20100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/africa\/wp-json\/wp\/v2\/tags?post=20100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}